DNM2 and mesothelioma: To evaluate the impact of VDAC1 silencing on differentiation of mesothelioma xenograft tumor cells, we determined the expression levels of biomarkers for this differentiation vimentin (Figure 9A,B); cytokeratenin5 (Figure 9A,B), a cytoskeletal protein; and calretinin, a calcium-binding protein (Figure 9C,D) [57,58,59] in si-m/hVDAC1-B-treated and si-NT-treated xenograft tumors using IF and specific antibodies (Figure 9).